Skip to main content
Latest News
March 9, 2026
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
March 6, 2026
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
March 2, 2026
Bristol Myers Squibb Announces Dividend
Latest Events
Event year list
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
October 29, 2026
08:00 AM ET
Bristol Myers Squibb Q3 2026 Results Conference Call
July 30, 2026
08:00 AM ET
Bristol Myers Squibb Q2 2026 Results Conference Call
April 30, 2026
08:00 AM ET
Bristol Myers Squibb Q1 2026 Results Conference Call